The second coming of angiogenesis inhibitors?

"So far, dozens of clinical trials have evaluated checkpoint inhibitor-angiogenesis inhibitor combos. Some proved toxic, and others failed. However, the studies also led FDA to approve new therapies for types of liver, kidney, lung, and endometrial cancers. The drug combinations are not curative, but they restrain tumor growth. And some extend patients’ lives by many months over angiogenesis inhibitors alone."

https://www.science.org/content/article/failed-cancer-therapy-revived-powerful-tumor-killer-when-combined-newer-drugs#.ZGTEnbmFjTk.linkedin